中南医学科学杂志2025，Vol.53Issue(3)：539-542,4.DOI:10.15972/j.cnki.43-1509/r.2025.03.040
血清GDF15、CXCL17与特应性皮炎严重程度及度普利尤单抗治疗有效性的关系
Association of changes in serum levels of GDF15 and CXCL17 with disease severity and dupi-lumab treatment efficacy in atopic dermatitis
摘要
Abstract
Aim To analyze the relationship between serum levels of growth differentiation factor 15(GDF15)and C-X-C motif-containing chemokine ligand 17(CXCL17)with disease severity and dupilumab treatment efficacy in atopic dermatitis(AD)pa-tients.Methods We enrolled 137 AD patients and stratified them into mild(n=38),moderate(n=53),and severe(n=46)groups based on SCORAD scores.The 76 patients receiving dupilumab treatment were further classified into effective(n=47)and ineffective(n=29)groups according to therapeutic response.Serum levels of GDF15 and CXCL17 were compared among groups,and their correlations were analyzed.Receiver operating characteristic(ROC)curves were used to evaluate the predictive value of GDF15 and CXCL17 for dupilumab treatment efficacy.Results SCORAD scores,IgE,GDF15,and CXCL17 levels showed an increase in an order of severe group＞moderate group＞mild group(P＜0.05).Compared with the effective group,the ineffective group demonstrated lower GDF15 and CXCL17 levels(P＜0.05).Both GDF15 and CXCL17 positively correlated with SCORAD scores and dupilumab treatment efficacy(P＜0.05).Serum GDF15 and CXCL17 exhibited good diagnostic value for predicting dupilumab effica-cy,with combined assessment showing superior performance to individual markers(P＜0.001).Conclusion Serum levels of GDF15 and CXCL17 closely associate with disease severity and dupilumab treatment efficacy in AD patients.关键词
特应性皮炎/GDF15/CXCL17/度普利尤单抗Key words
atopic dermatitis/gdf15/cxc117/dupilumab分类
医药卫生引用本文复制引用
武迎磊,赵天,袁耀辉..血清GDF15、CXCL17与特应性皮炎严重程度及度普利尤单抗治疗有效性的关系[J].中南医学科学杂志,2025,53(3):539-542,4.基金项目
邢台市重点研发计划项目(2022ZC178) （2022ZC178）
